Navigation Links
Targanta Submits Oritavancin New Drug Application
Date:2/11/2008

Candidate Represents Potential New Short-Course Treatment Option for

Serious Gram-Positive Skin Infections, Including MRSA

CAMBRIDGE, Mass., Feb. 11 /PRNewswire-FirstCall/ -- Targanta Therapeutics Corporation (Nasdaq: TARG) announced today that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its lead antibiotic candidate, oritavancin, a novel semi-synthetic lipoglycopeptide antibiotic candidate with potent bactericidal (killing) activity against a broad spectrum of gram-positive bacteria.

Oritavancin would be indicated for the treatment of complicated skin and skin structure infections (cSSSI) caused by gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). Targanta believes oritavancin's properties may offer distinct advantages in treating patients who have these serious infections.

The oritavancin NDA submission includes data from 19 clinical trials, including two pivotal Phase 3 clinical trials examining the safety and efficacy of oritavancin in the treatment of cSSSI, both of which met their primary endpoints. The NDA dossier also includes data from more than 2,100 individuals and in vitro activity data on oritavancin against more than 9,000 clinical bacterial isolates, including a broad range of gram-positive strains resistant to commonly used antibiotics such as oxacillin, methicillin, vancomycin, daptomycin, and linezolid.

"The NDA submission is a significant milestone for Targanta," said Mark Leuchtenberger, president and chief executive officer of Targanta. "We are proud to have taken this important first step towards providing the infectious disease community with a new candidate to combat the growing challeng
'/>"/>

SOURCE Targanta Therapeutics Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Targanta to Present at Lazard Capital Markets Fourth Annual Healthcare Conference
2. Targanta to Present at 9th Annual Mass Opportunities Investment Conference
3. Targanta Therapeutics Announces Pricing of its Initial Public Offering
4. Targanta Therapeutics to Have Significant Presence at 47th Annual ICAAC Meeting
5. MedImmune Submits Biologics License Application to FDA for Motavizumab
6. Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkins Lymphoma
7. Exelixis Submits XL139 Diligence Report to Bristol-Myers Squibb
8. Angiotech Submits 510(K) To FDA For Its Innovative 5-FU CVC
9. Cephalon Submits Supplemental New Drug Application for FENTORA
10. AMDL Submits Data to FDA for Clearance to Market Its DR-70(R) Diagnostic Test to Monitor Colorectal Cancer Patients
11. CV Therapeutics Submits Supplemental New Drug Application for Ranexa(R) (ranolazine extended-release tablets)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/1/2015)... IRVINE, CA (PRWEB) April 01, 2015 ... in Personalized Medicine , presented two scientific posters ... City, Utah, last week. The four-day event was hosted ... 2,000 genetic specialists dedicated to educating genetic and genomic ... Biosciences presented Genetics and Insomnia: Study on the Role ...
(Date:4/1/2015)... 1, 2014 /CNW/ - Canada,s Research-Based ... (PMPRB) newly released report on Cost Drivers of Public Drug ... according to the report, the rates of change in drug ... low of -0.8 percent in 2012/13 for a number of ... that examines the costs of medicines without considering their overall ...
(Date:4/1/2015)... and NEW YORK ... Inc. (NASDAQ:  PTBI), a biopharmaceutical company advancing protein ... provided an overview of the Company,s 2014 achievements ... achievements below demonstrate the progress the Company has ... multiple corporate partnerships for its MuGard programs, the ...
(Date:4/1/2015)...  Spherix Incorporated (Nasdaq: SPEX ) -- an intellectual ... monetization of intellectual property, today announced that Chardan ... global investment bank specializing in micro, small, and ... Spherix. The report, authored by ... Chardan, was published on March 31, 2015. The ...
Breaking Biology Technology:Proove Biosciences Presents Research Studies at Annual Clinical Genetics Meeting 2015 2Rx&D responds to PMPRB report: overall impact of medicines must always be considered 2PlasmaTech Biopharmaceuticals Provides Strategic Update for 2015 and Review of 2014 Acheivements 2PlasmaTech Biopharmaceuticals Provides Strategic Update for 2015 and Review of 2014 Acheivements 3PlasmaTech Biopharmaceuticals Provides Strategic Update for 2015 and Review of 2014 Acheivements 4PlasmaTech Biopharmaceuticals Provides Strategic Update for 2015 and Review of 2014 Acheivements 5PlasmaTech Biopharmaceuticals Provides Strategic Update for 2015 and Review of 2014 Acheivements 6Chardan Capital Issues Industry Note Covering Spherix 2Chardan Capital Issues Industry Note Covering Spherix 3
... Million Gift, NEW YORK, April 16 NYU ... renamed the NYU Elaine,A. and Kenneth G. Langone Medical ... trustees and his wife, whose unrestricted $200 million gift ... announcement was made by Robert I. Grossman, M.D.,( http://www.med.nyu.edu/people/grossr03.html ...
... CITY, April 16 /PRNewswire-FirstCall/ - Victhom Human Bionics,Inc. ... the ongoing,human clinical trial of its Closed-Loop neuromodulation ... of patients suffering from foot drop,secondary to a ... the,initial results of the trial have demonstrated that ...
... and Finger Health in Diabetes Management, ... Pelikan,Technologies Inc., a leading developer of ... Lilly and Company today announced the,signing of ... of the,co-promotion agreement, the companies will promote ...
Cached Biology Technology:NYU Medical Center Changes Name to Honor Chairman of Board & Wife 2NYU Medical Center Changes Name to Honor Chairman of Board & Wife 3NYU Medical Center Changes Name to Honor Chairman of Board & Wife 4NYU Medical Center Changes Name to Honor Chairman of Board & Wife 5Victhom announces promising results on the proof of concept for its unique closed-loop neuromodulation system 2Pelikan Technologies and Lilly Form Alliance to Promote Diabetes Education 2Pelikan Technologies and Lilly Form Alliance to Promote Diabetes Education 3Pelikan Technologies and Lilly Form Alliance to Promote Diabetes Education 4
(Date:3/18/2015)... 18, 2015 As mobile payments become ... smart wallets and apps continue to be introduced into the ... the mobile payment industry in focus today are:  NXT-ID, Inc. ... BABA ), Apple Inc. (NASDAQ: AAPL ... Inc. (NASDAQ: FB ) NXT-ID, Inc. ...
(Date:3/17/2015)... YORK , March 17, 2015  MecklerMedia ... the largest exhibition for service robots ever held ... RoboUniverse takes place on May 11-13, 2015 at ... and exhibitors for the event include: Acorn Product ... Control; EZ-Robot; Infranor; Kinova Robotics; Littler; NewBotic Corporation; ...
(Date:3/12/2015)... 2015 The mascots of the Atlantic Coast ... of Wake Forest Baptist Medical Center. They stopped by ... ACC Men,s Basketball Tournament. Young patients enjoyed bonding with ... their autographs. Brenner Children,s Hospital is the ... only children,s hospital in northwest North Carolina ...
Breaking Biology News(10 mins):Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 2Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 3Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 4Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 5Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 6MecklerMedia's RoboUniverse New York Announces Sponsors and Exhibitors, May 11-13, 2015 2
... pulmonary fibrosis (IPF) is a chronic and progressive lung disorder ... The disease is characterized by the insidious onset of dyspnea ... , Now, Selman and coworkers present in an article published ... May, strong evidence indicating that a subset of IPF patients ...
... at the first signs of cold weather. Rather, new research ... survive the chilly months. , These so-called "heat-shock proteins" ensure ... spring. , A study of flesh flies and a ... of protective heat-shock proteins that are turned on almost as ...
... for revealing anatomical details of soft tissues. Contrast agents ... allow physiological processes to be followed in real time. ... cannot reveal anatomic structures. As reported in the journal ... at Samsung Medical Center and Taeghwan Hyeon at Seoul ...
Cached Biology News:Extra-aggressive form of idiopathic pulmonary fibrosis identified 2For many insects, winter survival is in the genes 2For many insects, winter survival is in the genes 3